Member Info for Wiggly

I will go further.... I think the RECIST data might well surprise the market.

Doubtful AS would include reference to it unless it was 'black and white' akin to the biospy data, otherwise he would be best advised to stick to the positive safety profile rather than introducing the topic of efficacy.

I think there is chance AS will present a slide, similar to the biopsy data slide, providing some data on the disease progression topic - otherwise there was no need to include in the last RNS.

Not sure why so many get so stressed on the placing topic.

Ava6k is performing better than any expectations and has proven the entire pre|CISION platform.

Any furure placing, whether imminent or not, should not be feared at this stage.

If ava6k was a dud and the BOD stated no imminent placing you could rightly get stressed but that's not the case here.

I actually hope we do get some new II on board soon as we need strong hands to ensure AVA6K reaches its full valuation at buy out (which is fast approaching imo)

The longer we remain in the phase1a DE stage the more exciting and 'valuable' the asset becomes. Lots of eyes watching very closely now and wouldn't be surprised to see action before commencing phase1b.

I think the market is wakening up!

Be prepared to be pleasantly surprised. Im expecting > 6

To be included in the trial, Patients had to either have relapsed or progressed on SoC treatment or be intolerant or nonamenable to SoC treatment.

The fact we have 'several' patients continuing due to no disease progression is truly 'remarkable'. The significance of this is huge and Im sure the market will start to comprehend during the days ahead.

Key Inclusion Criteria:

* Patients who have either relapsed or progressed on SoC treatment or are intolerant or nonamenable to SoC treatment..

Experimental: AVA6000 Phase 1a

*Patients in Phase Ia will receive escalating doses of AVA6000 following a 3+3 design, commencing with a starting dose of 80mg/m2, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1), until disease progression..

https://classic.clinicaltrials.gov/ct2/show/NCT04969835

As things stand, all data obtained so far (pre clinical and clinical) supports the theory that AVA6k will be confirmed clinically superior vs straight dox (as per the DR Tap statement, at this point, AVA6K becomes standard of care overnight).

At the point clinical differentiation is confirmed beyond doubt (e.g. at completion of phase1b) Ava6k becomes a multi billion $ blockbuster asset that will be in demand from >1 entity. Demand from >1 entity = bidding = valuation that could be staggering.

We are not far away from being able to fully validate the clinical differentiation. With data on hand, we can assume very confidently that Ava6k is already proven to be clinically differentiated.

Has been said many times but there is no other share globally offering the Risk vs Reward that is offered here.

'The emerging positive safety and pharmacokinetic data from the study support the potential clinical differentiation of AVA6000 over doxorubicin. This includes: (i) higher dosing of AVA6000 compared to standard doxorubicin, (ii) more frequent dosing of AVA6000 compared to doxorubicin - doxorubicin is typically dosed every three weeks in order for patients to recover from the side effects of treatment, (iii) the ability to administer many more cycles of AVA6000 compared to doxorubicin'

Pathetic share price performance.

Unfortunately a buy out at many multiples lower than true value is now on the cards.

DTW

The RNS states the following:

'several patients in cohort 5 ***and earlier cohorts*** remain on treatment as their disease has not progressed.

There is a massive & rapidly growing gap between the AVCT MC and the preCISION asset value.

Many early-stage pharma assets (single assets, not platform techs) have been selling for multi billions.

I doubt there is any single asset out there that is as exciting, as low risk, as groundbreaking, as valuable (TAM) as AVA6K, never mind preCISION as a whole.

The huge valuation gap has to close soon.

With confirmation that patients from earlier CH's are still being dosed, this means that some patients have been dosed for >9 months e.g. CH 4, Sept start date

Very good point PL.

Today we will surely find out whether the market really is thick as mince!

Wow - I missed this bit with all the excitement.

The emerging positive safety and pharmacokinetic data from the study support the potential clinical differentiation of AVA6000 over doxorubicin. This includes: (i) higher dosing of AVA6000 compared to standard doxorubicin, (ii) more frequent dosing of AVA6000 compared to doxorubicin - doxorubicin is typically dosed every three weeks in order for patients to recover from the side effects of treatment, (iii) the ability to administer many more cycles of AVA6000 compared to doxorubicin.

Several patients remain on trial in different dose cohorts and continue to receive AVA6000 as their disease has not progressed

Major inflection news right there.

End of life patients and disease is not progressing.

Unbelievable

If the rumours are correct I think it's likely we are bringing on a new II (s) (big raise to sticky strategic partner) and the 10-20m referenced is for PI, management etc (sim to last raise) hence the leak.

All costs covered (and more) all the way to phase 2 and an II that will support achieving full value come confirmation of efficacy at end of phase1b.

The prize at that point is multi billions so not worried at all about raising now if it ensures we achieve full value at end of phase1b.

Terry - don't embarrass yourself. Avacta would not be progressing DE and opening up US sites, supported by Dr Tap, if there was not huge confidence in preCISION.

If major funding (I suspect through license) was not 100% nailed on, then this would seem a strange move to me.

I am therefore 100% sure we have a license deal in the pipeline. Perhaps the DE extension is being driven by new partner.

Good on him. Hopefully the industry comes out fighting on this. Truly ridiculous position from Labour.